What is DARA Biosciences Return-on-Tangible-Asset?
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. DARA Biosciences's annualizedNet Income for the quarter that ended in Sep. 2015 was €-9.62 Mil. DARA Biosciences's average total tangible assets for the quarter that ended in Sep. 2015 was €6.48 Mil. Therefore, DARA Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2015 was -148.35%.
The historical rank and industry rank for DARA Biosciences's Return-on-Tangible-Asset or its related term are showing as below:
FRA:PJUF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -179.48 Med: -108.86 Max: -14.04
Current: -93.74
During the past 13 years, DARA Biosciences's highest Return-on-Tangible-Asset was -14.04%. The lowest was -179.48%. And the median was -108.86%.
FRA:PJUF's Return-on-Tangible-Asset is not ranked
in the Biotechnology industry.
Industry Median: -40.55
vs FRA:PJUF: -93.74
DARA Biosciences Return-on-Tangible-Asset Historical Data
The historical data trend for DARA Biosciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DARA Biosciences's Return-on-Tangible-Asset
For the Biotechnology subindustry, DARA Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DARA Biosciences's Return-on-Tangible-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DARA Biosciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where DARA Biosciences's Return-on-Tangible-Asset falls into.
DARA Biosciences Return-on-Tangible-Asset Calculation
DARA Biosciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2014 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Sep. 2015) net income data.
DARA Biosciences (FRA:PJUF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
DARA Biosciences Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of DARA Biosciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:PJUF has been successfully added to your 